Company Encyclopedia
View More
name
MYL
600993.SH
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers first and second category medical devices, household products, electronic products, daily necessities, hygiene products, and disinfection products, as well as automobile freight services. In addition, the company is involved in the retail and wholesale of medical devices and medicines; provision of hospital and medical management service; and hospital operations.
3.157 T
600993.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking27/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.77%B
    • Profit Margin15.15%A
    • Gross Margin48.14%B
  • Growth ScoreB
    • Revenue YoY8.36%B
    • Net Profit YoY18.50%B
    • Total Assets YoY4.23%C
    • Net Assets YoY7.29%B
  • Cash ScoreB
    • Cash Flow Margin660.16%C
    • OCF YoY8.36%B
  • Operating ScoreB
    • Turnover0.72B
  • Debt ScoreA
    • Gearing Ratio17.03%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MYL: Subsidiary obtains drug registration certificate

    MYL announced that its subsidiary Jiangxi MYL Meikang Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Olopatadine Hydrochloride Eye Drops issued by the National Medical Products Administration. Olopatadine Hydrochloride Eye Drops are used to treat eye itching associated with allergic conjunctivitis

    Zhitong·
    SH
    600993
    +0.53%
    Zhitong·
    SH
    600993
    +0.53%

    Bank of China International: The Medical Insurance Bureau clarifies that centralized procurement is against involution, focusing on re-evaluation opportunities in the pharmaceutical sector

    Bank of China International released a research report stating that the Medical Insurance Bureau has launched the 11th batch of centralized procurement, emphasizing the principles of "stabilizing clinical practices, ensuring quality, preventing collusion, and resisting involution," while optimizing procurement rules. This centralized procurement will no longer simply reference the lowest price; companies with the lowest bids are required to publicly explain the rationale and commit to not quoting below cost. It is expected that as price expectations stabilize, the profitability of the pharmaceutical industry will gradually improve, and it is recommended to pay attention to the revaluation opportunities in the pharmaceutical sector

    Zhitong·
    SH
    603233
    -0.50%
    SH
    688621
    -1.60%
    SH
    600993
    +0.53%
    Zhitong·
    SH
    603233
    -0.50%
    SH
    688621
    -1.60%
    SH
    600993
    +0.53%

    MYL's subsidiary obtains drug registration certificate for sodium hyaluronate eye drops

    MYL's wholly-owned subsidiary, Jiangxi MYL Meikang Pharmaceutical Co., Ltd., recently obtained the sodium hyaluronate eye drops drug registration certificate issued by the National Medical Products Administration. This approval will enrich the company's ophthalmic product line and enhance market competitiveness

    Zhitong·
    SH
    600993
    +0.53%
    Zhitong·
    SH
    600993
    +0.53%

    CITIC Securities: Resuming coverage of MYL, rating Buy

    Zhitong·
    SH
    600993
    +0.53%
    Zhitong·
    SH
    600993
    +0.53%

    MYL released its first-quarter performance, with a net profit attributable to the parent company of 204 million yuan, a year-on-year increase of 2.99%

    According to the Zhitong Finance APP, MYL disclosed its first-quarter report for 2025, showing that the company achieved revenue of 969 million yuan during the reporting period, a year-on-year increase of 1.48%; net profit attributable to shareholders was 204 million yuan, a year-on-year increase of 2.99%; and net profit excluding non-recurring items was 195 million yuan, a year-on-year increase of 1.01%. The basic earnings per share were 0.47 yuan

    Zhitong·
    SH
    600993
    +0.53%
    Zhitong·
    SH
    600993
    +0.53%
    © 2025 Longbridge｜Disclaimer